Art. -Nr.: HY-N0453

Hypericin

8 Cited Publications

Kundenbewertung

Based on 8 publication(s) in Google Scholar

Hypericin is a naturally occurring substance found in Hyperlcurn perforatum L. Hypericin is an inhibitor of PKC (protein kinase C), MAO (monoaminoxidase), dopamine-beta-hydroxylase, reverse transcriptase, telomerase and CYP (cytochrome P450). Hypericin shows antitumor, antiviral, antidepressive activities, and can induce apoptosis.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.79%
CAS. Nr.: 548-04-9
Formel: C₃₀H₁₆O₈
Molecular Weight:504.44

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Hypericin Chemical Structure

CAS. Nr.: 548-04-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (8)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Antibiotic Isoform-spezifische Produkte anzeigen :

Alle Monoamine Oxidase Isoform-spezifische Produkte anzeigen :

MAO-A
MAO-B

Alle PKC Isoform-spezifische Produkte anzeigen :

Alle Cytochrome P450 Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	IC₅₀	0.3 μM Compound: 1	Inhibition of recombinant CRF1 receptor expressed in CHO cells assessed as inhibition of CRF-induced cAMP formation Inhibition of recombinant CRF1 receptor expressed in CHO cells assessed as inhibition of CRF-induced cAMP formation	[PMID: 20408551]
HaCaT	IC₅₀	1.7 μM Compound: 6p ; Hypericin	Antiproliferative (inhibition of cell growth) activity against HaCaT cells (human keratinocyte line) Antiproliferative (inhibition of cell growth) activity against HaCaT cells (human keratinocyte line)	[PMID: 9371243]

In Vitro

Hypericin (0.25-4 μM; 24 h) inhibits the growth of fibroblasts (Fb), melanocytes (Mc), and keratinocytes (Kc)^[2].
Hypericin (3 μM; 24 h) treatment can induce cells apoptosis^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

Fibroblasts (Fb), melanocytes (Mc), and keratinocytes (Kc)
Concentration:

0.25 μM; 0.5 μM; 1 μM; 2 μM; 3 μM; 4 μM
Incubation Time:

24 hours
Result:

Showed the LD₅₀ for Fb and Mc at 1.75 μM and 3.5 μM, respectively, and for Kc at a greater dose than 4 μM.

Apoptosis Analysis^[2]

Cell Line:

Fibroblasts (Fb), melanocytes (Mc), and keratinocytes (Kc)
Concentration:

3 μM
Incubation Time:

24 hours
Result:

Showed a significant (p<0.001) early apoptotic Fb population (64%), and a smaller, significant (p<0.05) early apoptotic Mc population (20%).

In Vivo

Hypericin (Intravenous injection; 10 mg/kg; once) treatment delays tumor growth^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

18-20 week-old female BALB/c mice injected with CT26 carcinomas^[3]
Dosage:

10 mg/kg
Administration:

Intravenous injection; 10 mg/kg; once
Result:

Showed a four times delayed tumor growth compared to the control groups.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 548-04-9
Appearance Solid
Molecular Weight 504.44
Formel C₃₀H₁₆O₈
Color Brown to black
SMILES

O=C1C2=C(O)C=C(O)C3=C2C4=C(C5=C6C(O)=CC(C)=C5C7=C4C1=C(O)C=C7C)C8=C3C(O)=CC(O)=C8C6=O
Structure Classification
- Quinones
- Anthraquinones
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (8)

All In Vivo Efficacy StudyWBCell Imaging/StainingIFFlow CytometryCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Short-chain acyl-CoA dehydrogenase initiates mtDNA demethylation and leakage to fuel antitumor immunity in colorectal cancer. [Abstract]

2026 Mar 26;11(1):113. PMID: 41888107
Carbon

2024 Sep.
Biomed Pharmacother

Novel antidepressant mechanism of hypericin: Role of connexin 43-based gap junctions. [Abstract]

2023 Nov:167:115545. PMID: 37734259

Hypericin purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2023 Nov:167:115545. [Abstract]

Hypericin (0.2 mg/kg, gavage). Changes in body weight. (csingle bondh) Behavioral tests: SPT. Quantitation of crossing number of rats in OFT. Rearing number of rats in OFT. The average speed of rats in OFT. Immobility time in FST.

Hypericin purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2023 Nov:167:115545. [Abstract]

Hypericin (0.2 mg/kg, gavage). Western blots and analysis showed that lower levels of Cx43 were restored by HY treatment in CUS rats. Representative bands of Cx43, p-Cx43 at Serine-368, and GAPDH. GAPDH was used as a loading control. Quantitation of Cx43/GAPDH, p-Cx43/GAPDH and p-Cx43/Cx43.

Hypericin purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2023 Nov:167:115545. [Abstract]

Hypericin (0.2 mg/kg, gavage). Immunofluorescent staining of p-Cx43. Cx43 or p-Cx43 was labeled with green fluorescence and nuclei were labeled by Hoechst 33342 with blue fluorescence. Scale bar: 200 µm.

Hypericin purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2023 Nov:167:115545. [Abstract]

Cell viability of CORT-treated astrocytes was improved by Hypericin (0.1, 0.5, 2.5 μM). Results were expressed as percentages of the Ctrl group. Data were obtained from six independent experiments and shown as the mean ± SEM.
Int J Nanomedicine

Hypericum Perforatum-Derived Exosomes-Like Nanovesicles: A Novel Natural Photosensitizer for Effective Tumor Photodynamic Therapy. [Abstract]

2025 Feb 4:20:1529-1541. PMID: 39925681

Hypericin purchased from MedChemExpress. Usage Cited in: Int J Nanomedicine. 2025 Feb 4:20:1529-1541. [Abstract]

WM-266-4 cells were co-cultured with different concentrations of HPDENs for 12 hours. The PBS group served as the negative control, while the Hypericin (0.2 μg/mL) group served as the positive control. Cells were then irradiated with an LED at 4 mW/cm² for 10 minutes or left untreated. Data are expressed as means ± SEM.

Hypericin purchased from MedChemExpress. Usage Cited in: Int J Nanomedicine. 2025 Feb 4:20:1529-1541. [Abstract]

Fluorescence microscopy images depict cellular reactive oxygen species levels following treatment with PBS, Hypericin (0.2 μg/mL), and HPDENs with or without LED illumination. Scale bar: 100 μm. Graphic represents cellular ROS levels observed in fluorescence microscopy images. n=3. Data are expressed as means ± SEM.

Hypericin purchased from MedChemExpress. Usage Cited in: Int J Nanomedicine. 2025 Feb 4:20:1529-1541. [Abstract]

Hypericin (0.2 μg/mL). Flow cytometry was employed to assess the expression of apoptosis-related genes in Annexin V-labeled cells. Quantitation of FITC-positive results obtained through flow cytometry. n=3. Data are expressed as means ± SEM.
Rheumatology (Oxford)

Autophagy inhibitors block pathogenic NET release in immune-mediated inflammatory disease without impairing host defence. [Abstract]

2025 Aug 13:keaf437. PMID: 40802538
Cancers (Basel)

Identification of New Vulnerabilities in Conjunctival Melanoma Using Image-Based High Content Drug Screening. [Abstract]

2022 Mar 19;14(6):1575. PMID: 35326726
Mol Immunol

Hypericin impedes M2 macrophage polarization and protects against Hepatocellular carcinoma. [Abstract]

2025 Mar 27:181:160-168. PMID: 40153953
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 250 mg/mL (495.60 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9824 mL

9.9120 mL

19.8240 mL

5 mM

0.3965 mL

1.9824 mL

3.9648 mL

10 mM

0.1982 mL

0.9912 mL

1.9824 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.08 mg/mL (4.12 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.08 mg/mL (4.12 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 2.08 mg/mL.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 10 mg/mL (19.82 mM); Suspended solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 0.5% CMC-Na/saline water

Solubility: 25 mg/mL (49.56 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (289 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. A Kubin, et al. Hypericin--the facts about a controversial agent. Curr Pharm Des. 2005;11(2):233-53. [Content Brief]

[2]. A Popovic, et al. Differential susceptibility of primary cultured human skin cells to hypericin PDT in an in vitro model. J Photochem Photobiol B. 2015 Aug;149:249-56. [Content Brief]

[3]. Renata Sanovic, et al. Low dose hypericin-PDT induces complete tumor regression in BALB/c mice bearing CT26 colon carcinoma. Photodiagnosis Photodyn Ther. 2011 Dec;8(4):291-6. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9824 mL	9.9120 mL	19.8240 mL	49.5599 mL
	5 mM	0.3965 mL	1.9824 mL	3.9648 mL	9.9120 mL
	10 mM	0.1982 mL	0.9912 mL	1.9824 mL	4.9560 mL
	15 mM	0.1322 mL	0.6608 mL	1.3216 mL	3.3040 mL
	20 mM	0.0991 mL	0.4956 mL	0.9912 mL	2.4780 mL
	25 mM	0.0793 mL	0.3965 mL	0.7930 mL	1.9824 mL
	30 mM	0.0661 mL	0.3304 mL	0.6608 mL	1.6520 mL
	40 mM	0.0496 mL	0.2478 mL	0.4956 mL	1.2390 mL
	50 mM	0.0396 mL	0.1982 mL	0.3965 mL	0.9912 mL
	60 mM	0.0330 mL	0.1652 mL	0.3304 mL	0.8260 mL
	80 mM	0.0248 mL	0.1239 mL	0.2478 mL	0.6195 mL
	100 mM	0.0198 mL	0.0991 mL	0.1982 mL	0.4956 mL

Hypericin

8 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Hypericin

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Kinase Inhibitor Library

Metabolism/Protease Compound Library

Neuronal Signaling Compound Library

TGF-beta/Smad Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Reprogramming Compound Library

Lipid Compound Library

Oxygen Sensing Compound Library

Cytoskeleton Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Mitochondria-Targeted Compound Library

Food-Sourced Compound Library

Rare Diseases Drug Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Antiviral Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Cancer Stem Cells Compound Library

Coagulation and Anti-coagulation Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Miao Ethnicity Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Mongolian Medicine Compound Library

Quinones Library

Natural Product Diversity Scaffold Library

RNA Binding Bioactive Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Hypericin

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Alle Monoamine Oxidase Isoform-spezifische Produkte anzeigen

Alle PKC Isoform-spezifische Produkte anzeigen

Alle Cytochrome P450 Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (8)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Hypericin Related Classifications

HY-N0453 Related Classifications